MedTrace Logo

Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

NCT07213076 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2026-01-21

No results posted yet for this study

Summary

This is a retrospective, observational study of treatment patterns and clinical outcomes in Australian EGFRm advanced and metastatic non-small cell lung cancer patients treated with first-line osimertinib or second-line osimertinib.

Conditions

Sponsors & Collaborators

  • Peter MacCallum Cancer Centre, Australia

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Marliese Alexander · Peter MacCallum Cancer Centre, Australia

  • Ben Solomon · Peter MacCallum Cancer Centre, Australia

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-04
Primary Completion
2025-11-10
Completion
2025-11-10

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07213076 on ClinicalTrials.gov